Abstract
Objectives: To evaluate the efficacy of alteration from gonadotropin-releasing hormone (GnRH) agonist to antagonist in patients with castration-resistant prostate cancer (CRPC). Methods: Fourteen patients with CRPC were switched from GnRH agonist to GnRH antagonist. CRPC was defined as 3 consecutive rises of PSA values under androgen deprivation therapy despite a testosterone level at the castration level. No patient underwent a change in oral anti-androgen agent or any additional therapy. Patients who showed increase of the PSA value within 10% or showed decrease in the PSA value compared to the baseline were defined as responders. We measured serum PSA, testosterone, follicular stimulating hormone (FSH), and leutenizing hormone (LH) at the time of alteration and 3 months after alteration. Results: The mean age at diagnosis was 74.8 ± 6.3 years with a mean initial PSA level of 537.3 ± 999.1 ng/mL. The mean age at alteration to GnRH antagonist was 81.4 years with a mean PSA level of 28.6 ng/mL. Two out of 14 patients (14%) were judged as responders based on PSA after alteration to GnRH antagonist, although they did not show any further reduction of the serum testosterone level (remain less than 0.03). Six patients showed further reduction of the serum FSH level after alteration; however, they showed no PSA response (from 46.4 ± 42.6 to 69.4 ± 70.3). Conclusions: The switch from GnRH agonist to GnRH antagonist affected 14% of the patients (2 out of 14 patients) with CRPC at 3 months based on PSA. Larger and longer-term studies are required to determine the efficacy of alteration to GnRH antagonist in patients with CRPC.
Highlights
Combined androgen blockade (CAB) with gonadotropin-releasing hormone (GnRH) agonist and anti-androgen is one of the important treatment options for patients with locally advanced or metastatic prostate cancer [1]
The switch from GnRH agonist to GnRH antagonist affected 14% of the patients (2 out of 14 patients) with castration-resistant prostate cancer (CRPC) at 3 months based on PSA
Multiple options for secondary treatment have been recommended for patients with castration-resistant prostate cancer (CRPC), such as alternative non-steroidal anti-androgen therapy after the exclusion of anti-androgen withdrawal syndrome, abiraterone [2] [3], enzalutamide [4] [5], lowdose steroid, estrogen preparation, and chemotherapy with docetaxel [6] or cabazitaxel [7]
Summary
Combined androgen blockade (CAB) with gonadotropin-releasing hormone (GnRH) agonist and anti-androgen is one of the important treatment options for patients with locally advanced or metastatic prostate cancer [1]. It was reported that GnRH antagonist could extend the duration of PSA recurrence compared with GnRH agonist [9]. Few studies have been reported on the efficacy of change from GnRH agonist to GnRH antagonist in patients with CRPC [10]. We assessed the utility of change from GnRH agonist to GnRH antagonist in patients with CRPC by measuring sequential changes in the values of PSA, testosterone, follicular stimulating hormone (FSH), and leutenizing hormone (LH)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
